Teva's Prospects Are Looking Up

We recommended Teva Pharmaceutical (TEVA) a number of times over the past two years in the $38 to $41 price range. The shares had been relatively dead money until 2014. However, over the past six months, the stock has shot up more than 34% to $54.00. We continue to like the name because of a number of positive business developments and the stock's modest valuation level of 11.3x earnings.  

The biggest overhang on Teva's share price over the past 24 months has been Copaxone, its industry-leading therapy drug for multiple sclerosis. Investors had feared that when Copaxone lost its patent protection in May 2014, that event would lead to a significant decline in Teva's earnings. This has not been the case....542 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.